Medicamen Biotech (MEDICAMEQ.NS) Stock Price
Medicamen Biotech Price
Revenue has compounded at 6.5% per year over the past 19 years to 1.98 B INR. Earnings per share have grown at 10.3% per year over the last 19 years. Medicamen Biotech's net margin stands at 4.9%, down from 12.9% several years earlier. Medicamen Biotech currently offers a dividend yield of about 0.67%. The payout ratio is around 23% of earnings. The dividend has grown at 18.9% per year over the past 4 years.
Medicamen Biotech stock price
Medicamen Biotech business model & stock analysis
Frequently asked questions about Medicamen Biotech
5 analysts currently rate the Medicamen Biotech stock: 4 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Medicamen Biotech share trades at 2.76 EUR (299.45 INR).
The revenue of Medicamen Biotech is 1.98 B INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Medicamen Biotech is 96.41 M INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Medicamen Biotech is currently 42.12. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medicamen Biotech stock.
The price-to-sales ratio (P/S) of Medicamen Biotech is currently 2.05. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medicamen Biotech stock.
The Eulerpool Quality Score for Medicamen Biotech is 6/10.
The ISIN of Medicamen Biotech is INE646B01010. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Medicamen Biotech is MEDICAMEQ.NS. The ticker symbol is used to trade Medicamen Biotech shares on the stock exchange.
Medicamen Biotech stock
Medicamen Biotech Peer Group
Medicamen Biotech FIGI
All fundamentals and in-depth analysis of Medicamen Biotech
Our stock analysis for Medicamen Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medicamen Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.